Lawmakers press Eli Lilly for China drug trials tied to military-linked hospitals

Lawmakers are pressing Eli Lilly over allegations and risks tied to its China clinical trials, especially where research involved hospitals linked to the military and facilities in Xinjiang. In a Tuesday letter, House Select Committee on the Chinese Communist Party chairman John Moolenaar asked Lilly to provide detailed information on its China operations, including how the company safeguards ethical standards, sensitive biotechnology, and intellectual property. The committee says public records show Lilly sponsored or collaborated on more than 220 clinical studies in China since 2003, including at least 11 trials involving Xinjiang and at least 16 involving Chinese military medical centers, with some still active. While noting it has “no evidence” of illegal wrongdoing, the inquiry raises national security, IP, and human rights concerns. The probe reflects intensifying scrutiny as U.S. firms expand ties with China.